Moberg Pharma AB (publ) (STO:MOB)
Sweden
· Delayed Price · Currency is SEK 11.48
-0.52 (-4.33%)
Apr 28, 2026, 5:29 PM CET
Moberg Pharma AB Revenue
In the year 2025, Moberg Pharma AB had annual revenue of 13.54M SEK with 37.99% growth. Moberg Pharma AB had revenue of 2.07M in the quarter ending December 31, 2025, with 101.36% growth.
Revenue
13.54M
Revenue Growth
+37.99%
P/S Ratio
39.86
Revenue / Employee
2.71M
Employees
6
Market Cap
539.57M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Enzymatica AB | 53.90M |
| Orexo AB | 26.00M |
| Dicot Pharma AB | 200.00K |
| EQL Pharma AB | 425.75M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
| Cereno Scientific AB | 44.27M |
Moberg Pharma AB News
- 6 months ago - Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential - PRNewsWire
- 1 year ago - Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU - PRNewsWire
- 1 year ago - Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients - PRNewsWire
- 2 years ago - Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98% - PRNewsWire